Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors
Nia JulianJune 17, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

Nia JulianJune 28, 2021
Next

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial

Nia JulianJune 15, 2021

© 2020 Solasta Ventures. All Rights Reserved.